Zinc Fingers nuclease News and Research

RSS

Researchers develop first non-human primate X-SCID models using genome editing techniques

Researchers affiliated with the Kawasaki INnovation Gateway at SKYFRONT, have successfully generated the first ever non-human primate X-SCID models by using two genome editing techniques. The findings were published in Cell Stem Cell, July 2016.

3 Jan 2017

Scientists develop genetically engineered T cells with fusion inhibitor to disrupt HIV's harpoon

When HIV attacks a T cell, it attaches itself to the cell's surface and launches a "harpoon" to create an opening to enter and infect the cells.

18 Nov 2016

Sangamo presents Phase 2 data from two ongoing clinical trials of SB-728-T for treatment of HIV/AIDS

Sangamo BioSciences, Inc., the leader in therapeutic genome editing, announced the presentation of Phase 2 data from two of the Company's ongoing clinical trials (SB-728-1101 Cohort 3* and SB-728-mR-1401) of SB-728-T, which is being developed for the functional control of HIV/AIDS.

11 Dec 2015

Sangamo BioSciences to present data on ZFP Therapeutic platform at ASGCT meeting

Sangamo BioSciences, Inc. announced that data from clinical, preclinical and research-stage programs focused on the development of ZFP Therapeutics will be presented at the 18th Annual Meeting of the American Society of Gene and Cell Therapy

29 Apr 2015

BioReliance inks non-exclusive license agreement with QTS for proprietary B-CLEAR technology

BioReliance, Sigma-Aldrich Corporation's biologics and early-development services business under SAFC Commercial, is pleased to announce a non-exclusive license agreement with Qualyst Transporter Solutions for its proprietary B-CLEAR technology.

21 Apr 2015

BeiGene chooses SAFC's CHOZN Platform to support oncology drug development

Sigma-Aldrich Corporation today announced that SAFC Commercial, its custom manufacturing services business unit, has entered a commercial sales and service contract with leading biopharmaceutical company, BeiGene.

11 Mar 2015

CIRM grants $5.6 million to develop HIV/AIDS therapeutic using Sangamo's ZFN genome-editing technology

Sangamo BioSciences, Inc. announced that the California Institute for Regenerative Medicine (CIRM) has granted a $5.6 million Strategic Partnership Award to fund clinical studies at City of Hope to develop a potentially curative ZFP Therapeutic for HIV/AIDS based on the application of Sangamo's zinc finger nuclease (ZFN) genome-editing technology in hematopoietic stem/progenitor cells (HSPCs).

31 May 2014

MGH investigators develop next-generation genome editing system

A next-generation genome editing system developed by Massachusetts General Hospital investigators substantially decreases the risk of producing unwanted, off-target gene mutations. In a paper receiving online publication in Nature Biotechnology, the researchers report a new CRISPR-based RNA-guided nuclease technology that uses two guide RNAs, significantly reducing the chance of cutting through DNA strands at mismatched sites.

26 Apr 2014

Horizon Discovery, Sirion Biotech ink supply and distribution agreement

Horizon Discovery, a leading provider of research tools to support translational genomics and the development of personalized medicines, today announced it has signed a supply and distribution agreement with Sirion Biotech GmbH.

17 Feb 2014

Biogen Idec, Sangamo BioSciences partner to develop therapeutics for hemoglobinopathies

Biogen Idec and Sangamo BioSciences, Inc. announced today an exclusive worldwide collaboration and license agreement focused on the development of therapeutics for hemoglobinopathies, inherited conditions that result from the abnormal structure or underproduction of hemoglobin.

9 Jan 2014

Horizon, AstraZeneca partner to explore oncology-relevant genotypes to identify novel drug targets

Horizon Discovery and AstraZeneca have entered into a research, collaboration and license agreement to explore a range of oncology-relevant genotypes with the aim of identifying and validating a number of novel drug targets. This deal is the second collaboration between AstraZeneca and Horizon, and follows the announcement in April 2013 of an oncology discovery program to explore Horizon's first-in-class kinase target program, HD-001.

7 Jan 2014

Sigma Life Science signs license agreement with Horizon Discovery for CompoZr ZFN technology

Sigma-Aldrich Corporation today announced that Sigma Life Science, its innovative biological products and services business, has entered a non-exclusive license agreement with Horizon Discovery for use of Sigma's CompoZr Zinc Finger Nuclease technology.

3 Sep 2013

Sigma Life Science releases genome editing tool for screening and exploratory studies

Sigma-Aldrich Corporation today announced that Sigma Life Science, its innovative biological products and services business, released Sigma CRISPRs, an inexpensive mammalian genome editing tool suitable for screening and exploratory studies.

27 Aug 2013

Discovery provides evidence that genetic defect responsible for Down syndrome can be suppressed

Scientists at the University of Massachusetts Medical School are the first to establish that a naturally occurring X chromosome "off switch" can be rerouted to neutralize the extra chromosome responsible for trisomy 21, also known as Down syndrome, a genetic disorder characterized by cognitive impairment.

18 Jul 2013

Sangamo BioSciences fourth quarter revenues increase to $8.9 million

Sangamo BioSciences, Inc. today reported fourth quarter and full year 2012 financial results and accomplishments.

7 Feb 2013

Data from Sangamo BioSciences’ SB-728-T Phase 1 clinical programs on HIV/AIDS

Sangamo BioSciences, Inc. announced that data from its Phase 1 clinical programs to develop SB-728-T, a novel therapeutic approach designed to generate a "functional cure" for HIV/AIDS, were presented at the 52nd Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC).

11 Sep 2012

Safer alternative to experimental gene therapy against HIV infection

Scientists at The Scripps Research Institute have discovered a surprisingly simple and safe method to disrupt specific genes within cells. The scientists highlighted the medical potential of the new technique by demonstrating its use as a safer alternative to an experimental gene therapy against HIV infection.

2 Jul 2012

Sigma-Aldrich acquires BioReliance

Sigma-Aldrich Corporation, a leading Life Science and High Technology company, announced it has completed its acquisition of BioReliance Holdings, Inc., a leading provider of global biopharmaceutical testing services, from Avista Capital Partners for $350 million in cash, subject to normal post-closing adjustments.

31 Jan 2012

Sangamo BioSciences starts Phase 2 clinical studies to develop functional cure for HIV/AIDS

Sangamo BioSciences, Inc. announced today the initiation of two new Phase 2 clinical studies (SB-728-1101 and SB-728-902, Cohort 5) in its program to develop a "functional cure" for HIV/AIDS.

9 Jan 2012

Nature publishes Sangamo's gene correction strategy for A1AT deficiency

Sangamo BioSciences, Inc. (Nasdaq: SGMO) announced the publication of a preclinical study demonstrating highly specific, functional correction of the alpha 1-antitrypsin (A1AT) gene defect in patient-derived induced pluripotent stem cells (iPSCs) using zinc finger nucleases.

14 Oct 2011